• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用微流控CEE™平台分离的循环肿瘤细胞中基于荧光原位杂交技术的HER2状态测定

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.

作者信息

Mayer Julie Ann, Pham Tam, Wong Karina L, Scoggin Jayne, Sales Edgar V, Clarin Trisky, Pircher Tony J, Mikolajczyk Stephen D, Cotter Philip D, Bischoff Farideh Z

机构信息

Biocept Inc., San Diego, CA, USA.

出版信息

Cancer Genet. 2011 Nov;204(11):589-95. doi: 10.1016/j.cancergen.2011.10.011.

DOI:10.1016/j.cancergen.2011.10.011
PMID:22200084
Abstract

Determination of HER2 status in breast cancer patients is considered standard practice for therapy selection. However, tumor biopsy in patients with recurrent and/or metastatic disease is not always feasible. Thus, circulating tumor cells (CTCs) are an alternative source of tumor cells for analysis of HER2. An antibody cocktail for recovery of variable, high- and low-, EpCAM-expressing tumor cells was developed based on FACS evaluation and then verified by CTC enumeration (based on CK and CD45 staining) with comparison to EpCAM-only and with CellSearch® (n=19). HER2 fluorescence in situ hybridization (FISH) on all (CK+ and CK-) captured cells was compared to HER2 status on the primary tumors (n=54) of patients with late stage metastatic/recurrent breast cancer. Capture of low EpCAM-expressing tumor cells increased from 27% to 76% when using the cocktail versus EpCAM alone, respectively. Overall, CTC detection with the OncoCEE™ platform was better compared to CellSearch® (68% vs. 89%, respectively), and a 93% concordance in HER2 status was observed. HER2 FISH analysis of CK+ and CK- CTCs is feasible using the CEE™ platform. Although larger clinical studies are warranted, the results demonstrate adequate sensitivity and specificity as needed for incorporation into laboratory testing.

摘要

确定乳腺癌患者的HER2状态被认为是治疗选择的标准做法。然而,对复发和/或转移性疾病患者进行肿瘤活检并不总是可行的。因此,循环肿瘤细胞(CTC)是分析HER2的肿瘤细胞的另一种来源。基于流式细胞术评估开发了一种用于回收表达可变、高和低EpCAM的肿瘤细胞的抗体鸡尾酒,然后通过CTC计数(基于细胞角蛋白和CD45染色)与仅使用EpCAM以及与CellSearch®(n = 19)进行比较进行验证。将所有(细胞角蛋白阳性和细胞角蛋白阴性)捕获细胞上的HER2荧光原位杂交(FISH)与晚期转移性/复发性乳腺癌患者原发肿瘤(n = 54)上的HER2状态进行比较。与单独使用EpCAM相比,使用该鸡尾酒时低EpCAM表达肿瘤细胞的捕获率分别从27%提高到76%。总体而言,与CellSearch®相比,使用OncoCEE™平台检测CTC的效果更好(分别为68%对89%),并且观察到HER2状态的一致性为93%。使用CEE™平台对细胞角蛋白阳性和细胞角蛋白阴性CTC进行HER2 FISH分析是可行的。尽管需要进行更大规模的临床研究,但结果表明其具有纳入实验室检测所需的足够敏感性和特异性。

相似文献

1
FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.使用微流控CEE™平台分离的循环肿瘤细胞中基于荧光原位杂交技术的HER2状态测定
Cancer Genet. 2011 Nov;204(11):589-95. doi: 10.1016/j.cancergen.2011.10.011.
2
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.转移性乳腺癌患者循环肿瘤细胞 HER2 状态:一项前瞻性、多中心试验。
Breast Cancer Res Treat. 2010 Nov;124(2):403-12. doi: 10.1007/s10549-010-1163-x. Epub 2010 Sep 22.
3
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.晚期乳腺癌患者原发肿瘤与相应循环肿瘤细胞 HER2 状态的相关性。
Breast Cancer Res Treat. 2009 Dec;118(3):523-30. doi: 10.1007/s10549-009-0461-7. Epub 2009 Jul 12.
4
Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.根据雌激素受体和HER2状态,细胞角蛋白-19 mRNA阳性循环肿瘤细胞在早期乳腺癌中的不同预后价值。
J Clin Oncol. 2007 Nov 20;25(33):5194-202. doi: 10.1200/JCO.2007.11.7762. Epub 2007 Oct 22.
5
Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.使用多标志物逆转录聚合酶链反应检测细胞角蛋白19、乳腺珠蛋白A和HER2对早期乳腺癌循环肿瘤细胞进行分子检测的预后价值。
Clin Cancer Res. 2008 May 1;14(9):2593-600. doi: 10.1158/1078-0432.CCR-07-4758.
6
A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation.一种在CellSearch分离后对乳腺癌循环肿瘤细胞进行下游表征的新方法。
J Transl Med. 2015 Apr 21;13:126. doi: 10.1186/s12967-015-0493-1.
7
HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients.人表皮生长因子受体2(HER2)阳性循环肿瘤细胞表明I至III期乳腺癌患者的临床预后较差。
Clin Cancer Res. 2006 Mar 15;12(6):1715-20. doi: 10.1158/1078-0432.CCR-05-2087.
8
Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer.治疗晚期乳腺癌过程中循环肿瘤细胞 HER2 状态与原发肿瘤相比的变化。
Clin Breast Cancer. 2010 Oct 1;10(5):392-7. doi: 10.3816/CBC.2010.n.052.
9
Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.采用共聚焦显微镜检测法对乳腺癌循环肿瘤细胞中 HER2 的表达进行定量测定。
Oncol Rep. 2010 Feb;23(2):423-8.
10
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status.乳腺癌患者的中枢神经系统复发与晚期、循环中隐匿肿瘤细胞的存在以及HER2/neu状态相关。
Breast Cancer Res. 2006;8(4):R36. doi: 10.1186/bcr1516.

引用本文的文献

1
Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review.胰腺导管腺癌的血液生物标志物:过去十年的进展及未来展望——综述
Front Oncol. 2025 Apr 22;15:1555963. doi: 10.3389/fonc.2025.1555963. eCollection 2025.
2
Microfluidics engineering towards personalized oncology-a review.面向个性化肿瘤学的微流控工程——综述
In Vitro Model. 2023 Jul 13;2(3-4):69-81. doi: 10.1007/s44164-023-00054-z. eCollection 2023 Aug.
3
Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
曲妥珠单抗-德鲁替康治疗 HER2 表达可变的乳腺癌脑膜转移患者的持久应答。
J Neurooncol. 2024 Oct;170(1):209-217. doi: 10.1007/s11060-024-04788-y. Epub 2024 Jul 29.
4
Targeting circulating tumor cells to prevent metastases.针对循环肿瘤细胞以预防转移。
Hum Cell. 2024 Jan;37(1):101-120. doi: 10.1007/s13577-023-00992-6. Epub 2023 Oct 24.
5
Breast cancer circulating tumor cells with mesenchymal features-an unreachable target?具有间质特征的乳腺癌循环肿瘤细胞——一个无法企及的目标?
Cell Mol Life Sci. 2022 Jan 20;79(2):81. doi: 10.1007/s00018-021-04064-6.
6
Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.评估曲妥珠单抗联合长春瑞滨治疗 HER2 阴性肿瘤和 HER2 阳性循环肿瘤细胞的晚期乳腺癌患者的 II 期单臂研究。
JCO Precis Oncol. 2021 Nov;5:896-903. doi: 10.1200/PO.20.00461.
7
Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSide™ Assay.通过使用 CNSide™ 检测法在脑脊液中识别肿瘤细胞,对患有乳腺癌的女性进行脑膜转移的诊断。
Clin Breast Cancer. 2022 Jun;22(4):e457-e462. doi: 10.1016/j.clbc.2021.11.002. Epub 2021 Nov 14.
8
Circulating tumor cells: biology and clinical significance.循环肿瘤细胞:生物学和临床意义。
Signal Transduct Target Ther. 2021 Nov 22;6(1):404. doi: 10.1038/s41392-021-00817-8.
9
Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.从循环肿瘤细胞基因组不稳定性的角度看肿瘤进化和治疗选择。
Cells. 2021 Feb 5;10(2):337. doi: 10.3390/cells10020337.
10
Performance evaluation of a high-throughput separation system for circulating tumor cells based on microcavity array.基于微腔阵列的循环肿瘤细胞高通量分离系统的性能评估
Eng Life Sci. 2020 Jul 14;20(11):485-493. doi: 10.1002/elsc.202000024. eCollection 2020 Nov.